You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: CAPSULOMICS INC Topic: 102
Esophageal squamous cell carcinoma (ESCC) causes more than 509,000 deaths per year worldwide, and over 80% of these cases occur in low- and middle-income countries (LMICs). In the settings where it is available and affordable, ESCC diagnosis is made using the highly invasive and expensive procedure known as esophagogastroduodenoscopy (EGD, also referred to as upper endoscopy). However, citizens of ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's DiseaseSBC: WELLSIM BIOMEDICAL TECHNOLOGIES INC Topic: NIA
PROJECT SUMMARY / ABSTRACT Alzheimerandapos;s disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extra ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: L2 DIAGNOSTICS LLC Topic: NIAID
ABSTRACTLyme disease, the most common vector-borne illness in North America, is caused by the spirochete B. burgdorferi. Infection begins in the skin following an infected tick-bite and acute illness is characterized by headache, fever and myalgia. Currently, there is no human vaccine against Lyme disease and therapeutic administration of antibiotics remains the recommended treatment option. In th ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical ProstatectomySBC: MICROCURES INC Topic: 300
Radical prostatectomy (RP) is a commonly used treatment option for localized prostate cancer, which carries a high risk for development of erectile dysfunction (ED) because of cavernous nerve (CN) injury. Even newer, nerve-sparing, robotic procedures do not convincingly improve erectile function (EF) outcomes after RP. In addition, ED resulting from RP is often refractory to treatment by orally ad ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: KLEIN BUENDEL, INC. Topic: 102
Physical activity (PA) is a modifiable risk factor for a number of preventable chronic diseases, including cardiovascular disease, strokes, obesity, and diabetes. These conditions constitute health disparities for African American men. Behavioral interventions have proven to be effective in promoting increases in physical activity. While behavior change programs have been shown to assist participa ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: VELUM INC Topic: 300
Project Summary Morbidity associated with neuronal degeneration and dysfunction poses an increasing public health burden. Among the wide range of etiologies that result in neuronal dysfunction, including chronic conditions such as Alzheimer’s and Parkinson’s disease and vascular dementias, one major cause that has been largely unnoticed but is increasingly recognized as a major concern is trau ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: VELUM INC Topic: NIA
Project Summary There is a world-wide “twin epidemic” of obesity and Type 2 Diabetes (T2D), with an urgent need to find effective new drug treatments for inducing weight loss. Stable derivatives of the endogenous glucoregulatory hormone, glucagon-like peptide-1 (GLP1) are in clinical use for the treatment of T2D but are also of great interest as an emerging treatment of obesity. Another closel ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: InnoTech Precision Medicine, Inc Topic: NIDCR
Original Abstract A multimodal platform for Oral screening of COVID-19 The development of a rapid and reliable sensor system from readily available oral specimens is crucial for the screening and management of SARS-CoV-2 infection. Other than tests that require laboratory-scale instrumentation, the development of rapid tests can play a timely role in the management of an outbreak. Current rapid te ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
Using Rendever to improve the quality of life of older adults with cognitive impairments in senior living communities and their family members who live at a distance.SBC: RENDEVER, INC. Topic: NIA
The United States is experiencing a public health crisis on a massive scale due to the number of people with dementia, lack of cures, and challenges associated with caregiving for this population.1,2 Until cures for the dementias are discovered, new technologies and interventions are imperative that can reduce the stress and emotional burden of Alzheimerandapos;s disease (AD) and Alzheimerandapos; ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: CORNOVUS PHARMACEUTICALS INC. Topic: NHLBI
PROJECT SUMMARY Current therapy for ischemic stroke is limited and new treatment is needed since the mortality and morbidity of subjects with this condition remain high. Effort aimed at blocking immune cell- mediated inflammation represents a novel approach. The specific background for the proposed project is that we have identified the myeloid P2X4 receptor (P2X4R), which induces inflammation, as ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health